Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 5, 2016, Pages 621-630

  Walker, M ^a   El Serag, H B ^a,b   Sada, Y ^a,b   Mittal, S ^a,b   Ying, J ^b   Duan, Z ^b   Richardson, P ^a,b   Davila, J A ^a,b   Kanwal, F ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; AGE; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; ADULT; HEALTH SERVICE; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; UTILIZATION; VETERAN;

ADULT; AGE FACTORS; AGED; COMORBIDITY; FEMALE; HEALTH SERVICES; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SOCIOECONOMIC FACTORS; VETERANS;

EID: 84955073742     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13505     Document Type: Article

References (31)

1. El-Serag HB,. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
2. El Serag HB, Siegel AB, Davila JA, et al,. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44: 158-66.
3. Lencioni R,. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-73.
4. Kanwal F, Befeler A, Chari RS, et al,. Potentially curative treatment in patients with hepatocellular cancer-results from the liver cancer research network. Aliment Pharmacol Ther 2012; 36: 257-65.
5. Davila JA, Kramer JR, Duan Z, et al,. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology 2013; 57: 1858-68.
6. Artinyan A, Mailey B, Sanchez-Luege N, et al,. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010; 116: 1367-77.
7. Lok AS, Seeff LB, Morgan TR, et al,. HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48.
8. Yang JD, Kim WR, Coelho R, et al,. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 64-70.
9. Mittal S, Sada YH, El-Serag HB, et al,. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13: 594-601.
10. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB, et al,. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52: 132-41.
11. Llovet JM, Bru C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
12. Executive Summary of The Third Report of The. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
13. Singal AG, Yopp AC, Gupta S, et al,. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012 Sep; 5 (9): 1124-30.
14. White DL, Kanwal F, El-Serag HB,. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-59.
15. Paradis V, Zalinski S, Chelbi E, et al,. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-9.
16. Ertle J, Dechene A, Sowa JP, et al,. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-43.
17. Mittal S, El-Serag HB, Sada YH, et al,. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans: an emerging disease entity associated with non-alcoholic fatty liver disease. Gastroenterology 2014; 146: S-917.
18. Menon KV, Hakeem AR, Heaton ND,. Review article: liver transplantation for hepatocellular carcinoma- a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014; 40: 893-902.
19. McGowan CE, Edwards TP, Luong MU, Hayashi PH,. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol 2015; 13: 799-804.
20. Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG,. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015; 13: 791-8.
21. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
22. Chou R, Wasson N,. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158: 807-20.
23. Angulo P, Hui JM, Marchesini G, et al,. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
24. Asrani S,. Incorporation of noninvasive measures of liver fibrosis into clinical practice: diagnosis and prognosis. Clin Gastroenterol Hepatol 2015; 13: 2190-204.
25. Karsdal MA, et al,. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases-early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014; 40: 233-49.
26. Cui J, et al,. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 2015; 41: 1271-80.
27. Singal AG, et al,. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015; 128: 90e-1.
28. El-Serag HB, Davila JA,. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011; 4: 5-10.
29. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
30. Holmberg SD, Spradling PR, Moorman AC, Denniston MM,. Hepatitis C in the United States. N Engl J Med 2013; 368: 1859-61.
31. Scaglione S, Kliethermes S, Cao G, et al,. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015; 13: 690-6.